secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001000694-25-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax reports Q4 revenue $88M, net loss $81M; transitions COVID vaccine to Sanofi; guides 2025 adj revenue $300-350M
--------------------------------------------------------------------------------

- Q4 2024 revenue $88M (vs $291M YoY); full year $682M (vs $984M). Product sales $50M vs $251M.
- Net loss narrowed to $81M in Q4 (vs $178M); full year loss $187M (vs $545M). Cash $938M at Dec 31, 2024.
- Transitioned Nuvaxovid commercial lead to Sanofi for 2025-2026 season. BLA target action date April 2025; $175M milestone upon approval.
- Sold Czech facility to Novo Nordisk for $200M; gain of $52M, annual cost savings ~$80M.
- 2025 guidance: combined R&D+SG&A $475-525M; adjusted licensing/royalties/other revenue $300-350M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000100069425000006/0001000694-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000100069425000006/nvax-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001000694-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer